Supplementary Figure 1. miR-216a negatively regulates non-small cell lung cancer cell growth. Supplementary Figure 2. miR-216a induces apoptosis in vitro and in vivo. Supplementary Figure 3. miR-216a inhibits EMT in non-small cell lung cancer cell. Supplementary Figure 4. Anti-Argonaute 2 RIP-Chip assay shows that overexpression of miR-216a increased Ago2 complex and ZEB1/eIF4B mRNA interaction. Supplementary Figure 5. Correlation of ZEB1/eIF4B expression and miR-216a expression or non-small cell lung cancer (NSCLC) patients' survival. Supplementary Figure 6. Effects of miR-216a on putative target genes expression in A549 and HepG2 cells. Supplementary Figure 7. Expression of miR-216a, ZEB1 and eIF4B. A549 cells were tranfected with indicated plasmid.
ARTICLE ABSTRACTPurpose: The aim of the present study is to investigate the role and mechanism of miR216a in non–small-cell lung cancer (NSCLC).Experimental Design: The expression of miR216a in NSCLC cell lines and from NSCLC patient specimens was measured by real-time qRT-PCR. The correlation between gene expression and patient survival was analyzed using Kaplan–Meier methods. The effects of miR216a on NSCLC cell growth and metastasis were examined both in vitro and in vivo by overexpressing or inhibiting miR216a. Finally, the effect of miR216a on chemoresistance was investigated by MTT assay and flow cytometry.Results: miR216a expression was downregulated in specimens from patients with NSCLC compared with corresponding nontumor lung tissues. Clinical data indicate that decreased miR216a expression is inversely correlated with cancer stage, metastasis, and poor survival in patients with NSCLC. Our data also show that overexpression of miR216a suppresses NSCLC cell growth and metastasis, and enhances cisplatin-induced cell growth inhibition and apoptosis. In contrast, inhibition of miR216a stimulates NSCLC cell growth and metastasis, and suppresses cisplatin-induced cell growth inhibition and apoptosis. Furthermore, we demonstrate that miR216a exerts its role by directly targeting eIF4B and ZEB1.Conclusion: Our findings suggest that miR216a is a cancer suppressor miRNA and that overexpression of miR216a is a novel NSCLC treatment strategy. In addition, our clinical data indicate that miR216a may be a useful biomarker for predicting NSCLC progression. Clin Cancer Res; 20(17); 4705–16. ©2014 AACR.